Concepedia

661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Robert J. Motzer, Nizar M. Tannir, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Elizabeth R. Plimack, Camillo Porta, Saby George, T.B. Powles,

Annals of Oncology · 2021 · 37 citations · 0 references

DOI

Concepts